Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.93 +0.68 (+0.67%)
Streaming Delayed Price Updated: 11:20 AM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Merck & Co., Inc.
Via Business Wire
Building Sustainable Value for Our Business and Society
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Exposures COVID-19
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Via FinancialNewsMedia
Celebrating the Diversity of Our Workforce
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Exposures COVID-19
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
From Merck & Co., Inc.
Via Business Wire
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
From Merck & Co., Inc.
Via Business Wire
Improving Medical Care in the Black Community With Family Health Histories
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
From Merck & Co., Inc.
Via Business Wire
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
From Merck & Co., Inc.
Via Business Wire
Employees Help Evacuate Patients From Record Flood in China
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
From Merck & Co., Inc.
Via Business Wire
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
From Merck & Co., Inc.
Via Business Wire
Leslie A. Brun Resigns from Merck Board of Directors
From Merck & Co., Inc.
Via Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
Via FinancialNewsMedia
Exposures COVID-19
Merck Has Been Named One of the Top Employers in New York by Fortune
SOURCE: Merck & Co., Inc. 
Via 3BL Media
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
From Merck & Co., Inc.
Via Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Merck Named by Seramount As One of the Best Companies for Multicultural Women
SOURCE: Merck & Co., Inc. 
Via 3BL Media
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
From Merck & Co., Inc.
Via Business Wire
Merck Has Earned the Top Spot on Forbes' 2021 List of 'Best Employers for New Graduates'
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Second-Quarter 2021 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Recognized on Best Places to Work for Disability Inclusion List and Received Perfect Score on the Disability Equality Index (DEI)
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Supply Chain
Exposures Supply Chain
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.